Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

BACKGROUND: The cardiovascular (CV) safety of linagliptin was evaluated in subjects with type 2 diabetes (T2DM). METHODS: Pre-specified patient-level pooled analysis of all available double-blind, randomized, controlled trials, ≥12 weeks’ duration (19 trials, 9459 subjects) of linagliptin versus pla...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cardiovasc Diabetol
Autors principals: Rosenstock, Julio, Marx, Nikolaus, Neubacher, Dietmar, Seck, Thomas, Patel, Sanjay, Woerle, Hans-Juergen, Johansen, Odd Erik
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4465456/
https://ncbi.nlm.nih.gov/pubmed/25990013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-015-0215-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars